Patents valid through 2038 Clinical topline results from Phase 2b ALS trial expected in H2 2023 Corresponding patents have b...
“While shocking, this move by Johnson & Johnson is unfortunately not surprising – we demand that the company halt its profiteering tactics ...
News Highlights: Brain Bio-Digital Twin technology has the potential to change medical treatment practices by eliminating the need for invasive and cost...
Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigim...
Genetic Technologies Limited (GTG), a pioneering global leader in genomics-based tests focused on health, wellness, and the battle against serious diseases...
SomaLogic’s SomaScan® platform was used to target 15 markers shared among all cancer types. In a new paper published in Nature's Scientific Repo...
What You Need to Know Individuals 5 years of age and older regardless of previous vaccination are eligible to receive a single dose of an updated mRNA C...
The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the treatment of ...
Second commercialized product strengthens Clover’s leading respiratory vaccine franchise and financial profile-- Clover Biopharmaceutica...
US-based startup Zenas BioPharma has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialise ob...
The principal investigator, Jennifer Ellis, PhD, Associate Professor of Psychiatry and Behavioral Sciences, JHU School of Medicine will be supported by co-...
The aim of the LOVE-DEB Study (Large de-NOVo coronary artEry disease treated with sirolimus Drug Eluting Balloon: prospective evaluation of safety & ef...
“We are building a new ecosystem in global public health,” said Anuradha Gupta, President of Global Immunization at Sabin. “We aim to cre...
ISA Pharmaceuticals B.V., a clinical-stage biotech company developing immunotherapies to treat cancers and serious infectious diseases, is pleased to ...
© 2025 Biopharma Boardroom. All Rights Reserved.
